Arcutis Pharmaceuticals

49 articles about Arcutis Pharmaceuticals

• Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 02, 2023

  11/2/2023

  Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 52,500 restricted stock units of Arcutis’ common stock to eight newly hired employees.

• New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials

  10/20/2023

  Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new individual patient response data showing nearly all individuals (95%) treated with ZORYVE® (roflumilast) cream 0.3% had a measurable improvement in Psoriasis Area and Severity Index (PASI).

• Arcutis Announces Proposed Public Offering - October 19, 2023

  10/19/2023

  Arcutis Biotherapeutics, Inc. announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.

• Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress

  10/13/2023

  Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new data from its pivotal ARRECTOR Phase 3 trial of roflumilast foam 0.3% for the treatment of adults and adolescents with scalp and body psoriasis.

• Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 05, 2023

  10/5/2023

  Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported the grant of inducement awards to L. Todd Edwards, its new Chief Commercial Officer.

• Arcutis to Present at Upcoming September 2023 Investor Conference

  9/5/2023

  Arcutis Biotherapeutics, Inc., an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, announced that Arcutis management will participate in an upcoming investor conference.

• Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%  

  8/29/2023

  Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the launch of The Cream That Can, the first commercial direct-to-consumer ad for ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents.

• Arcutis Appoints Interim Chief Financial Officer (CFO)Former and First Arcutis CFO, John Smither, Appointed Interim

  8/18/2023

  Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced that John W. Smither, who served as Arcutis’ first Chief Financial Officer from 2019 to 2021, has been appointed interim CFO effective August 31.

• Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 04, 2023

  8/4/2023

  Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported the grant of an aggregate of 38,500 restricted stock units of Arcutis’ common stock to five newly hired employees.

• Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark

  7/17/2023

  Arcutis Biotherapeutics, Inc. announced that ZORYVE® cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on CVS Caremark’s largest national commercial formularies effective July 5.

• Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 05, 2023

  7/5/2023

  Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 60,250 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 18,000 shares of Arcutis’ common stock to seven newly hired employees.

• Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 05, 2023

  6/5/2023

  Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 58,250 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 17,000 shares of Arcutis’ common stock to seven newly hired employees.

• Arcutis Announces Leadership Transition

  5/24/2023

  Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced a leadership change.

• Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 03, 2023

  2/3/2023

  Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 50,250 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 8,000 shares of Arcutis’ common stock to seven newly hired employees.

• Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis

  1/14/2023

  Arcutis Biotherapeutics, Inc. announced new safety and efficacy durability data from its open label Phase 2 long-term safety study evaluating once-daily roflumilast cream in adults with chronic plaque psoriasis.

• Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 05, 2023

  1/5/2023

  Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 17,050 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 33,550 shares of Arcutis’ common stock to five newly hired employees.

• Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 05, 2022

  12/5/2022

  Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported the grant of an aggregate of 8,000 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 18,000 shares of Arcutis’ common stock to two newly hired employees.

• Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis

  10/21/2022

  Arcutis Biotherapeutics, Inc. announced results of a nationwide survey of adults with seborrheic dermatitis and the healthcare providers who treat them that highlights the long path to diagnosis and the general lack of awareness and education about the disease.

• Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 05, 2022

  10/5/2022

  Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 32,300 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 85,800 shares of Arcutis’ common stock to nine newly hired employees.

• Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis

  9/26/2022

  Arcutis Biotherapeutics, Inc. today announced positive topline results from the ARRECTOR Pivotal Phase 3 trial evaluating roflumilast foam 0.3%, a once-daily, non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents with scalp and body psoriasis.